T. A. Palchevskaya

T. A. Palchevskaya

Auto-generated profile, based on publicly available information

T. A. Palchevskaya

Kyiv National University of Technologies and Design

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1990 in Journal of Molecular Catalysis
Verified
Journal Article
Closed access
VBV.M. Belousov
V.M. Belousov
TPT.A. Palchevskaya
T.A. Palchevskaya
LBL.V. Bogutskaya
L.V. Bogutskaya
LZL.A. Zyuzya
L.A. Zyuzya

26 August 2021 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ТПТ. А. Пальчевська
Т. А. Пальчевська
ОСО. О. Салій
О. О. Салій
ОБО. П. Баула
О. П. Баула
КПК. В. Пальчевський
К. В. Пальчевський
OOO. M. Onіshchuk
O. M. Onіshchuk
At the present stage of development of the pharmaceutical industry, the use of many functional excipients (DopR), which are important components of pharmaceutical formulations, becomes relevant. DopR is one of the most influential biopharmaceutical factors on the therapeutic efficacy of drugs, increasing the therapeutic effect and safety of active pharmaceutical ingredients (APIs) through the formation of optimal compounds and appropriate dosage forms by chemical modification of the molecule responsible for pharmacological activity. The purpose of the work is to analyze the literature on determining the role of excipients of trometamol and meglumine as biopharmaceutical factors in drugs of different pharmacotherapeutic groups; summarize and systematize data on their impact on the bioavailability of finished drugs. The objects of the study are excipients trometamоlum (TНAM) and meglumine (MGA) in the composition of drugs of different pharmacotherapeutic groups. Methods of a systematic approach, bibliographic, information retrieval, generalization and analysis were used in the research. A systematic study of the composition of drugs of the State Register of Medicinal Products (January 2021) showed that chemically modified drugs are supplied to the pharmaceutical market not only by domestic manufacturers, but also by pharmaceutical companies from 16 countries. The general nomenclature of drugs makes 82 trade names, from them 66% – with TMM and 34% – with MGA. A significant number of chemically modified insoluble and sparingly soluble APIs of different pharmacotherapeutic groups indicates a significant role of TMM and IGA in the development of new effective drugs. Thus, organic aminoproton acceptors: trometamol and meglumine – many functional excipients that increase the activity of active molecules, their release from dosage forms, stimulate the pharmacotherapeutic effect of drugs aimed at activating the protective forces (sanogenesis) and compensatory mechanisms of the body and thus, improve the pharmacological properties of drugs, reduce the risk of adverse reactions.

1 September 1988 in Reaction Kinetics, Mechanisms and Catalysis
Verified
Journal Article
Closed access
PDF file
VBV. M. Belousov
V. M. Belousov
TPT. A. Palchevskaya
T. A. Palchevskaya
LBL. V. Bogutskaya
L. V. Bogutskaya

1 February 2021 in News of Pharmacy
Verified
Journal Article
Open access
PDF file
OSO. Saliy
O. Saliy
OLO. Los
O. Los
TPT. Palchevska
T. Palchevska
KNK. Nebylytsia
K. Nebylytsia
Aim. To implement the Quality by Design (QbD) approach in order to develop the composition and the manufacturing technology of injectable hyaluronate sodium (HS) in combination with chondroitin sulfate (CS) for intra-articularintroduction. Materials and methods. The composition of the solution for injection was developed using samples of the active pharmaceutical ingredient (API) of HS and CS. The approaches of the ICH international guidelines were used to create the QbD protocol. The quality target product profile (QTPP) was developed based on the literature review, analysis of similar drugs and the previous in-house experimental studies. Determination of critical quality assessment (CQA) product indicators was performed by risk analysis for all quality indicators listed in QTPP. The risk assessment of quality indicators was performed by assessing them according to the Risk Priority Number system (hereinafter – RPN) by a 9-point scale. When studying the composition and the manufacturing technology of the injectable solution the quality risk management (QRM) was developed according to the Ishikawa diagram. Results and discussion. It has been found that the QbD concept is a systematic approach to the drug development. At the first stage QTPP was developed. Based on the QTPP data the CQA indicators were determined, and quality risks were assessed. The critical process parameters (CPP) of the solution for injection based on HS and CS, their control methods, as well as the critical material attributes (CMA) were determined. Based on the data obtained the drug control strategy was proposed taking into account the need to minimize the repetition of control experiments. Using the Isikawa diagram the variability of the material and the process with the environmental factors affecting the qualityof the solution for injection with HS and CS was shown.Conclusions. Using the basic QbD approaches when developing the composition and the manufacturing technology of an injectable drug for intra-articular introduction it has been found that the route of administration, dose, potency, and consumer properties of the product are important aspects of QTPP. It has been proven that the quality indicators, such as transparency, viscosity, sterility and the quantitative content of API are determined as CQA to achieve the objectives defined in QTPP. The study shows that almost all stages of production are critical, therefore, they need to be constantly monitored and checked to obtain a quality product. In further experimental studies to confirm the composition developed and the manufacturing technology according to QRM it is necessary to focus on such indicators as the solution temperature, stabilization time, degassing mode and filtration conditions.

29 August 2022 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ОСО. О. Салій
О. О. Салій
ЄСЄ. В. Саченко
Є. В. Саченко
ТПТ. А. Пальчевська
Т. А. Пальчевська
VSV. V. Strashnyi
V. V. Strashnyi
Currently, the global increase in resistance of pathogens to widely used antibiotics requires a return to the practice of using some classic drugs with preserved activity, finding new ways and directions of delivery of antibiotics to the locations of pathogenic microorganisms and the use of antimicrobial drugs that are not yet resistant. Doxycycline refers to antimicrobial drugs that do not yet have widespread resistance. Numerous studies of doxycycline have now been described as enhancing therapeutic effects, including COVID-19-related diseases, and finding new delivery routes to limit systemic side effects associated with high doses and avoid antibiotic resistance. The aim of the work was to analyze modern ways of doxycycline delivery, to determine the prospects for use in pharmacy, to summarize and systematize data on its functional purpose in the development of drugs with specified pharmaco-technological parameters. It is established that in the Ukrainian pharmaceutical market the range of drugs based on doxycycline hyclate is represented only by solid oral dosage forms - tablets and capsules for immediate release, but in the global pharmaceutical market there are additional dosage forms that provide parenteral delivery of doxycycline and oral forms. suspensions, syrups, dispersed tablets and delayed-release dosage forms – tablets, capsules and granules, which are the basis for the development of domestic drugs based on doxycycline. Development of new dosage forms with modified DH, such as implants, aerosols, lyophilisate for solution for injection, development of new manufacturing technologies, selection of excipients and delivery systems can improve the pharmacological action of antibiotics by reducing the dose and frequency of administration, prolonged or controlled programming. , and expanding the range of therapeutic action. Doxycycline is promising in pharmaceutical practice for the treatment of COVID-19, both due to its ability to inhibit matrix metalloproteinases (MMPs) and antiviral activity, especially against Mycoplasma pneumoniae, which is a secondary bacterial cause of pneumonia during the COVID-19 pandemic.

1 March 1987 in Reaction Kinetics, Mechanisms and Catalysis
Verified
Journal Article
Closed access
PDF file
VBV. M. Belousov
V. M. Belousov
TPT. A. Palchevskaya
T. A. Palchevskaya
LZL. A. Zyuzya
L. A. Zyuzya